Completed
This public workshop provided an opportunity for stakeholders to examine the current use of in-home drug disposal systems with a focus on removing unused opioid analgesics from the home.
FDA issued a request for information associated with this workshop, comments can be found at the Federal Register.
Featured publication
Workshop
ยท2024
The proper disposal of unused or expired prescription drugs, particularly controlled substances such as opioids, may help to prevent serious risk of nonmedical use or overdose. In June 2023, the National Academies Forum on Drug Discovery, Development, and Translation hosted a hybrid public workshop...
View details
Description
A planning committee of the National Academies of Sciences, Engineering, and Medicine will organize a public workshop on the development and use of in-home drug disposal systems with a focus on removing unused opioid analgesics from the home.
The public workshop will feature invited presentations and discussions to:
- Explore the types of in-home drug disposal options, other than mail back envelopes, that could be used to remove unused opioid analgesics from the home.
- Examine the current landscape of laws and regulations that apply to in-home opioid disposal systems.
- Discuss scientific, behavioral, health equity, and policy considerations for assessing the safety, use, and effectiveness of in-home opioid disposal systems, including the following questions:
- What is known/unknown about the methods (e.g., sequestration, adsorption, absorption) used in in-home disposal systems for rendering opioids unavailable for nonmedical use, assuming the product is used as intended?
- What approaches/methodologies are needed to evaluate the safe and correct use of in-home opioid disposal systems in real-world settings?
- How could person-centered design inform the development and use of in-home opioid disposal systems?
- Consider potential strategies for encouraging and assessing the development and use of in-home opioid disposal systems that support the public health goal of mitigating the risk of nonmedical use or overdose associated with opioids.
The planning committee will organize the workshop, develop the agenda, select and invite speakers and discussants, and moderate or identify moderators for the discussions. A proceedings of the presentations and discussions at the workshop will be prepared by a designated rapporteur in accordance with institutional guidelines.
Collaborators
Committee
Elizabeth McGinty
Co-Chair
Alastair J. Wood
Co-Chair
Mark C. Bicket
Member
Irene Z. Chan
Member
Ruchi Fitzgerald
Member
Lewis Grossman
Member
Stephen Hoag
Member
Kathy McNamara
Member
Robert Morones
Member
Tom Prisinzano
Member
Thabet Tolaymat
Member
Jessica Young
Member
Patricia Zettler
Member
Carolyn Shore
Staff Officer
Sponsors
Amgen Inc
Association of American Medical Colleges
AstraZeneca
Biogen
Burroughs Wellcome Fund
Critical Path Institute
Eli Lilly and Company
FasterCures, Milken Institute
Foundation for the National Institutes of Health
Friends of Cancer Research
Johnson & Johnson
Medable
Merck & Co., Inc.
National Cancer Institute
National Center for Advancing Translational Sciences
National Institute of Allergy and Infectious Diseases
National Institute of Mental Health
National Institute of Neurological Disorders and Stroke
New England Journal of Medicine
Office of the Director (National Institutes of Health)
Sanofi
Takeda
U.S. Food and Drug Administration
Staff
Carolyn Shore
Lead
Noah Ontjes
Melvin Joppy
Kyle Cavagnini